Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”
Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifil™ in Respiratory Syncytial Virus Infections
Pneumagen Appoints Scientific Advisory Board
Publication – Sialic Acid-Binding Protein Sp2CBMTD Protects Mice against Lethal Challenge with Emerging Influenza A (H7N9) Virus
PUBLICATION – Prevention of influenza by targeting host receptors using engineered proteins
Bio€quity Europe in San Sebastian, Spain | May 12th – 14th 2024
BioTrinity in London | April 23 – 24th 2024
J.P. Morgan Healthcare Conference and Biotech Showcase I January 8th – 11th 2024
Jefferies London Healthcare Conference I November 14th – 16th 2023
BARDA Industry Day in Washington I November 13th-14th 2023
BIO-Europe in Munich I November 6th-8th 2023
Bio€quity Europe in Dublin | May 14th – 16th 2023
BioTrinity in London | April 25 – 26th 2023
Biotech Showcase / JPM Week | January 9th – 11th 2023
Website powered by 100% renewable energy